86 completed, 37 recruiting, 31 terminated, 15 active not recruiting. 131 Phase 2, 50 Phase 1, 13 Not applicable, 11 Phase 3, 5 Early Phase 1.
Follow TBI: new trials by email Literature Review of TBI trials Research Report on TBI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 45 | 2026-09-01 | 2026-07-23 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
| MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases Treosulfan, Fludarabine, Total Body Irradiation - AML, MDS | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 132 | 2026-04-10 | 2026-04-16 |
| Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2025-09-26 | 2026-07-20 |
| Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Aplastic Anemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 1 | 2025-09-25 | 2026-05-22 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) 131I-apamistmab, Sirolimus, Campath - Sickling Disorder Due to Hemoglobin S | Phase 1 | Recruiting | Columbia University | 24 | 2025-04-28 | 2026-06-10 |
| A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL TMLI, TBI, Cyclophosphamide - Acute Lymphoblastic Leukemia, Pediatric | Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 276 | 2025-03-17 | 2025-02-18 |
| A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL TBI, TMLI, Cyclophosphamide - Acute Lymphoblastic Leukemia, Adult | Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 170 | 2025-03-01 | 2025-02-18 |
| A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL TBI, TMLI, Cyclophosphamide - Acute Lymphoblastic Leukemia, Pediatric | Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 170 | 2025-03-01 | 2025-02-18 |
| A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL TBI, TMLI, Cyclophosphamide - Acute Lymphoblastic Leukemia, Adult | Phase 2 | Recruiting | The First Affiliated Hospital of Zhengzhou University | 276 | 2025-03-01 | 2025-02-18 |
| Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation - Multiple Myeloma | Phase 1 | Recruiting | Washington University School of Medicine | 16 | 2024-12-04 | 2026-03-11 |
| Allo HSCT for High Risk Hemoglobinopathies Alemtuzumab, Total Body Irradiation, Cell Infusion - Graft Failure, Sickle Cell Disease | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 62 | 2024-11-19 | 2026-06-04 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide - Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 54 | 2024-07-23 | 2026-10-26 |
Showing 20 of 186. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (72) · Leukemia, Myeloid, Acute (70) · Myelodysplastic Syndromes (49) · Lymphoma, Non-Hodgkin (43) · Leukemia, Lymphocytic, Chronic, B-Cell (42) · Multiple Myeloma (42) · Hodgkin Disease (38) · Leukemia (31) · Lymphoma, Follicular (31) · Burkitt Lymphoma (30) · Lymphoma, Mantle-Cell (30) · Leukemia, Myelomonocytic, Chronic (28) · Lymphoma, B-Cell, Marginal Zone (28) · Myeloproliferative Disorders (28) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (26)
Fred Hutchinson Cancer Center (51) · Masonic Cancer Center, University of Minnesota (22) · M.D. Anderson Cancer Center (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (10) · National Cancer Institute (NCI) (9) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (8) · City of Hope Medical Center (4) · The First Affiliated Hospital of Zhengzhou University (4) · Columbia University (3) · Memorial Sloan Kettering Cancer Center (3) · Roswell Park Cancer Institute (3) · St. Anna Kinderkrebsforschung (3) · Affiliated Hospital to Academy of Military Medical Sciences (2) · Case Comprehensive Cancer Center (2) · Center for International Blood and Marrow Transplant Research (2)
United States (168) · Italy (14) · Germany (12) · Canada (8) · China (7) · Australia (4) · Austria (3) · Denmark (3) · France (3) · Czechia (2) · Israel (2) · Netherlands (2) · Poland (2) · Slovakia (2) · Sweden (2)
Brenda Sandmaier (11) · David Maloney (5) · Neal Flomenberg, MD (4) · Phuong Vo (4) · Daniel J. Weisdorf, MD (3) · Dolores Grosso, DNP, CRNP (3) · George Georges (3) · Marie Bleakley (3) · Ajay Gopal (2) · Amy E DeZern, MD (2) · Ann Woolfrey (2) · Claudio G. Brunstein, MD, PhD (2) · Erica Warlick, MD (2) · Filippo Milano (2) · George Chen (2)
PMID 32499241, PMID 33242441, PMID 15812540, PMID 18997171, PMID 21195303, PMID 21403127, PMID 22430088, PMID 22555974, PMID 25753432, PMID 32343796, PMID 35007144, PMID 18698002, PMID 19167681, PMID 19179301, PMID 19706886, PMID 19786617, PMID 19900571, PMID 21508125, PMID 21508413, PMID 21816832, PMID 21868572, PMID 22517900, PMID 22796534, PMID 23234514, PMID 23344397, PMID 23650429, PMID 24077845, PMID 24077846, PMID 24319166, PMID 24319167, PMID 24497539, PMID 24842530, PMID 25085357, PMID 25354103, PMID 25432172, PMID 25605857, PMID 25797174, PMID 25824692, PMID 25862561, PMID 26053664, PMID 26183076, PMID 26359881, PMID 26764356, PMID 26869630, PMID 26869631, PMID 28396162, PMID 2889870, PMID 29189665, PMID 29242852, PMID 29353109
P30CA015704 (27), P01CA018029 (13), P01CA078902 (8), P01CA015396 (3), P01CA044991 (3), P01HL036444 (2), P30CA016672 (2), P30CA033572 (2), P30CA043703 (2), U10CA180888 (2), U24CA076518 (2), 1RC2HL101496 (1), K23HL084054 (1), KL2RR025006 (1), P01CA049639 (1)